Although vemurafenib is a BRAF mutant inhibitor with high selectivity and efficacy against metastatic melanoma with BRAF V600 and non-V600E mutations [38], treatment resistance develops in most patients [40]. This evidence concerns the gene BRAF and metastatic melanoma.